Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

NCT06793826 · clinicaltrials.gov ↗

COMPLETED

Status

713

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B
Haemophilus Influenzae Type b Immunisation

Interventions

BIOLOGICAL: DTaP-IPV-Hep B-PRP-T combined vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company